Contributions of advanced proteomics technologies to cancer diagnosis

The ability of Medicine to effectively treat and cure cancer is directly dependent on their capability to detect cancers at their earliest stages. The advent of proteomics has brought with it the hope of discovering novel biomarkers in the early phases of tumorigenesis that can be used to diagnose diseases, predict susceptibility, and monitor progression. This discipline incorporates technologies that can be applied to complex biosystems such as serum and tissue in order to characterize the content of, and changes in, the proteome induced by physiological changes, benign or pathologic. These tools include 2-DE, 2D-DIGE, ICAT, protein arrays, MudPIT and mass spectrometries including SELDI-TOF. The application of these tools has assisted to uncover molecular mechanisms associated with cancer at the global level and may lead to new diagnostic tests and improvements in therapeutics. In this review these approaches are evaluated in the context of their contribution to cancer biomarker discovery. Particular attention is paid to the promising contribution of the ProteinChip/SELDI-TOF platform as a revolutionary approach in proteomic patterns analysis that can be applied at the bedside for discovering protein profiles that distinguish disease and disease-free states with high sensitivity and specificity. Understanding the basic concepts and tools used will illustrate how best to apply these technologies for patient benefit for the early cancer detection and improved patient care.

[1]  H. Kreipe,et al.  SELDI-MS-based expression profiling of ductal invasive and lobular invasive human breast carcinomas. , 2005, Pathology, research and practice.

[2]  X. Xiao,et al.  Development of Proteomic Patterns for Detecting Lung Cancer , 2004, Disease markers.

[3]  E. Diamandis.  Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. , 2004, Journal of the National Cancer Institute.

[4]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[5]  Shu Zheng,et al.  Artificial Neural Networks Analysis of Surface-Enhanced Laser Desorption/Ionization Mass Spectra of Serum Protein Pattern Distinguishes Colorectal Cancer from Healthy Population , 2004, Clinical Cancer Research.

[6]  K. Chong-Kook,et al.  Identification of hemoglobin‐α and ‐β subunits as potential serum biomarkers for the diagnosis and prognosis of ovarian cancer , 2005, Cancer science.

[7]  Lei Zhang,et al.  Accurate Qualitative and Quantitative Proteomic Analysis of Clinical Hepatocellular Carcinoma Using Laser Capture Microdissection Coupled with Isotope-coded Affinity Tag and Two-dimensional Liquid Chromatography Mass Spectrometry* , 2004, Molecular & Cellular Proteomics.

[8]  T. Pawlik,et al.  Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein , 2006, BMC Cancer.

[9]  F. Bertucci,et al.  Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. , 2002, The American journal of pathology.

[10]  S. De Flora,et al.  Proteomic analysis as related to transcriptome data in the lung of chromium(VI)-treated rats. , 2004, International journal of oncology.

[11]  William E Grizzle,et al.  Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  P. Speckman,et al.  Proteomic analysis of nipple aspirate fluid using SELDI‐TOF‐MS , 2005, International journal of cancer.

[13]  C. Bohring,et al.  Immune infertility: towards a better understanding of sperm (auto)-immunity. The value of proteomic analysis. , 2003, Human reproduction.

[14]  D. Chan,et al.  Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. , 2005, Clinical chemistry.

[15]  T. Beach,et al.  Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects , 2006, Neurological research.

[16]  E. Diamandis.  Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool , 2004, Molecular & Cellular Proteomics.

[17]  Stephen Russell,et al.  Proteomics of breast carcinoma. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[18]  D. Chan,et al.  Identification of Biomarkers for Breast Cancer in Nipple Aspiration and Ductal Lavage Fluid , 2005, Clinical Cancer Research.

[19]  T. Colgan,et al.  Protein expression profiling of endometrial malignancies reveals a new tumor marker: chaperonin 10. , 2004, Journal of proteome research.

[20]  Xiao-Ying Meng,et al.  Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. , 2005, Clinical chemistry.

[21]  Yi-ding Chen,et al.  World Journal of Gastroenterology , 2022 .

[22]  J. Albar,et al.  Differential proteomics: an overview of gel and non-gel based approaches. , 2004, Briefings in functional genomics & proteomics.

[23]  V. Gnau,et al.  Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair wise tissue proteomic and immunohistochemical analysis , 2006, Proteomics.

[24]  M. Ünlü,et al.  Difference gel electrophoresis. A single gel method for detecting changes in protein extracts , 1997, Electrophoresis.

[25]  R. Bast,et al.  Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer , 2004, Cancer Research.

[26]  Jos H Beijnen,et al.  Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. , 2006, World journal of gastroenterology.

[27]  Kym Faull,et al.  Characterization of serum biomarkers for detection of early stage ovarian cancer , 2005, Proteomics.

[28]  K. Lillemoe,et al.  Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. , 2002, Cancer research.

[29]  U. Settmacher,et al.  Discovery and identification of alpha-defensins as low abundant, tumor-derived serum markers in colorectal cancer. , 2005, Gastroenterology.

[30]  E. Petricoin,et al.  Early detection: Proteomic applications for the early detection of cancer , 2003, Nature Reviews Cancer.

[31]  S. Gygi,et al.  Haptoglobin-α subunit as potential serum biomarker in ovarian cancer: Identification and characterization using proteomic profiling and mass spectrometry , 2003 .

[32]  P. Schellhammer,et al.  Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. , 2001, Cancer research.

[33]  S. Gygi,et al.  Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[34]  D. Chan,et al.  Serum Diagnosis of Pancreatic Adenocarcinoma Using Surface-Enhanced Laser Desorption and Ionization Mass Spectrometry , 2004, Clinical Cancer Research.

[35]  Mario Plebani,et al.  Proteomics: the next revolution in laboratory medicine? , 2005, Clinica chimica acta; international journal of clinical chemistry.

[36]  Gilbert S Omenn,et al.  Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype. , 2006, Journal of proteome research.

[37]  H. Tajiri,et al.  Identification of serum proteins related to adverse effects induced by docetaxel infusion from protein expression profiles of serum using SELDI ProteinChip system. , 2005, Anticancer research.

[38]  P. Højrup,et al.  Use of mass spectrometric molecular weight information to identify proteins in sequence databases. , 1993, Biological mass spectrometry.

[39]  Nasreen S Jessani,et al.  A streamlined platform for high-content functional proteomics of primary human specimens , 2005, Nature Methods.

[40]  D. Chan,et al.  The Application of Clinical Proteomics to Cancer and other Diseases , 2003, Clinical chemistry and laboratory medicine.

[41]  J. Yates,et al.  Automated identification of amino acid sequence variations in proteins by HPLC/microspray tandem mass spectrometry. , 2000, Analytical chemistry.

[42]  M. Hung,et al.  Systemic tumor suppression by the proapoptotic gene bik. , 2002, Cancer research.

[43]  Hong Wang,et al.  Protein profiles associated with survival in lung adenocarcinoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[44]  B. Adam,et al.  Identification of patients with head and neck cancer using serum protein profiles. , 2004, Archives of otolaryngology--head & neck surgery.

[45]  D. Ward,et al.  Identification of serum biomarkers for colon cancer by proteomic analysis , 2006, British Journal of Cancer.

[46]  Michael J Dunn,et al.  Use of proteomics to discover novel markers of cardiac allograft rejection. , 2004, Journal of proteome research.

[47]  S. Gygi,et al.  Quantitative analysis of complex protein mixtures using isotope-coded affinity tags , 1999, Nature Biotechnology.

[48]  A. Alaiya,et al.  Clinical cancer proteomics: promises and pitfalls. , 2005, Journal of proteome research.

[49]  E. Petricoin,et al.  Proteomics of human breast ductal carcinoma in situ. , 2002, Cancer research.

[50]  S. Hanash,et al.  Integrated global profiling of cancer , 2004, Nature Reviews Cancer.

[51]  E. Diamandis.  Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? , 2003, Clinical chemistry.

[52]  C. Paweletz,et al.  Proteomic analysis of human bladder tissue using SELDI approach following microdissection techniques. , 2005, Methods in molecular biology.

[53]  F. Bosch,et al.  Proteomic analysis reveals successive aberrations in protein expression from healthy mucosa to invasive head and neck cancer , 2007, Oncogene.

[54]  M. Mann,et al.  Stable Isotope Labeling by Amino Acids in Cell Culture, SILAC, as a Simple and Accurate Approach to Expression Proteomics* , 2002, Molecular & Cellular Proteomics.

[55]  Nan Hu,et al.  2D Differential In-gel Electrophoresis for the Identification of Esophageal Scans Cell Cancer-specific Protein Markers* , 2002, Molecular & Cellular Proteomics.

[56]  F. von Eggeling,et al.  Biomarker Discovery and Identification in Laser Microdissected Head and Neck Squamous Cell Carcinoma with ProteinChip® Technology, Two-dimensional Gel Electrophoresis, Tandem Mass Spectrometry, and Immunohistochemistry* , 2003, Molecular & Cellular Proteomics.

[57]  Günther Ernst,et al.  Different expression of calgizzarin (S100A11) in normal colonic epithelium, adenoma and colorectal carcinoma. , 2006, International journal of oncology.

[58]  Stephen Alexander,et al.  Proteomic Analysis to Identify Breast Cancer Biomarkers in Nipple Aspirate Fluid , 2004, Clinical Cancer Research.

[59]  E. Fung,et al.  SELDI-TOF-MS proteomics of breast cancer , 2005, Clinical chemistry and laboratory medicine.

[60]  T. Barrette,et al.  Profiling of cancer cells using protein microarrays: discovery of novel radiation-regulated proteins. , 2001, Cancer research.

[61]  G. Wright,et al.  Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. , 2001, The American journal of pathology.

[62]  B. Martin,et al.  Peptide profiling in epithelial tumor plasma by the emerging proteomic techniques. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[63]  M. J. Chalmers,et al.  Clinical proteomics: a question of technology. , 2004, Rapid communications in mass spectrometry : RCM.

[64]  D. L. Diamond,et al.  Use of ProteinChip™ array surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) to identify thymosin β-4, a differentially secreted protein from lymphoblastoid cell lines , 2003, Journal of the American Society for Mass Spectrometry.

[65]  William C Reinhold,et al.  Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[66]  G. Wright,et al.  Proteinchip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures , 1999, Prostate Cancer and Prostatic Diseases.

[67]  J. Hoheisel,et al.  Antibody microarrays: An evaluation of production parameters , 2003, Proteomics.

[68]  T. Colgan,et al.  Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. , 2005, Journal of proteome research.

[69]  C. Hew,et al.  Proteomic Analysis of Colorectal Cancer Reveals Alterations in Metabolic Pathways , 2006, Molecular & Cellular Proteomics.

[70]  J R Yates,et al.  Mass spectrometry. From genomics to proteomics. , 2000, Trends in genetics : TIG.

[71]  Pierre Bedossa,et al.  Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases , 2005, Hepatology.

[72]  K. Baggerly,et al.  Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma , 2004, Cancer.

[73]  T. Veenstra,et al.  The Human Plasma Proteome , 2004, Molecular & Cellular Proteomics.

[74]  J. Seilhamer,et al.  A comparison of selected mRNA and protein abundances in human liver , 1997, Electrophoresis.

[75]  Wei Zhao,et al.  Mutations of PIK3CA in gastric adenocarcinoma , 2005, BMC Cancer.

[76]  Richard M Caprioli,et al.  Molecular profiling of experimental Parkinson's disease: direct analysis of peptides and proteins on brain tissue sections by MALDI mass spectrometry. , 2004, Journal of proteome research.

[77]  P. Schellhammer,et al.  Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.

[78]  Zhaosheng Lin,et al.  Application of SELDI-TOF mass spectrometry for the identification of differentially expressed proteins in transformed follicular lymphoma , 2004, Modern Pathology.

[79]  C. Huck,et al.  Biomarker discovery in breast cancer serum using 2‐D differential gel electrophoresis/ MALDI‐TOF/TOF and data validation by routine clinical assays , 2006, Electrophoresis.

[80]  A. Scarpa,et al.  Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[81]  G. Wright,et al.  Generation of a baculovirus recombinant prostate-specific membrane antigen and its use in the development of a novel protein biochip quantitative immunoassay. , 2000, Protein expression and purification.

[82]  E. Fung,et al.  Proteomic approaches to tumor marker discovery. , 2002, Archives of pathology & laboratory medicine.

[83]  R D Appel,et al.  Protein identification and analysis tools in the ExPASy server. , 1999, Methods in molecular biology.

[84]  Biaoyang Lin,et al.  Proteins Associated with Cisplatin Resistance in Ovarian Cancer Cells Identified by Quantitative Proteomic Technology and Integrated with mRNA Expression Levels*S , 2006, Molecular & Cellular Proteomics.

[85]  D. Jed Harrison,et al.  Application of Microfluidic Devices to Proteomics Research , 2002, Molecular & Cellular Proteomics.

[86]  Troels Z. Kristiansen,et al.  Biomarker Discovery from Pancreatic Cancer Secretome Using a Differential Proteomic Approach*S , 2006, Molecular & Cellular Proteomics.

[87]  D. Loegering,et al.  Proteomic analysis of mantle-cell lymphoma by protein microarray. , 2005, Blood.

[88]  Thomas P Conrads,et al.  The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. , 2002, Biochemical and biophysical research communications.

[89]  F. von Eggeling,et al.  Detection and identification of heat shock protein 10 as a biomarker in colorectal cancer by protein profiling , 2006, Proteomics.

[90]  T. Yip,et al.  Identification of Serum Amyloid A Protein As a Potentially Useful Biomarker to Monitor Relapse of Nasopharyngeal Cancer by Serum Proteomic Profiling , 2004, Clinical Cancer Research.

[91]  K. Kozak,et al.  Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[92]  Sylvia Heeneman,et al.  Proteomic analysis of differential protein expression in human atherosclerotic plaque progression , 2005, The Journal of pathology.

[93]  Brian B Haab,et al.  Antibody Arrays in Cancer Research , 2005, Molecular & Cellular Proteomics.

[94]  Y. Kato,et al.  Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform. , 2003, Biochemical and biophysical research communications.

[95]  T. Kang,et al.  Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons , 2003, Proteomics.

[96]  P. Alken,et al.  Protein Profiling of Bladder Cancer Using the 2D-PAGE and SELDI-TOF-MS Technique , 2006, Technology in cancer research & treatment.

[97]  E. Petricoin,et al.  Serum proteomic patterns for detection of prostate cancer. , 2002, Journal of the National Cancer Institute.

[98]  S. Flibotte,et al.  Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. , 2005, Clinical chemistry.

[99]  T. Enomoto,et al.  Altered protein expression in endometrial carcinogenesis. , 2005, Cancer letters.

[100]  S. Gammeltoft,et al.  Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study , 2005, BMC Cancer.

[101]  T. Colgan,et al.  A strategy for high‐resolution protein identification in surface‐enhanced laser desorption/ionization mass spectrometry: Calgranulin A and chaperonin 10 as protein markers for endometrial carcinoma , 2005, Proteomics.

[102]  P. O’Farrell.  High resolution two-dimensional electrophoresis of proteins. , 1975, The Journal of biological chemistry.

[103]  D. Chan,et al.  Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.

[104]  Walter Kolch,et al.  The molecular make-up of a tumour: proteomics in cancer research. , 2005, Clinical science.

[105]  M. Deeg,et al.  Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients , 2004, Laboratory Investigation.

[106]  T. Yip,et al.  New desorption strategies for the mass spectrometric analysis of macromolecules , 1993 .

[107]  Victor G Zgoda,et al.  Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1 , 2005, Proteomics.

[108]  S. Engelhardt,et al.  Proteomics strategies in cardiovascular research. , 2004, Journal of proteome research.

[109]  G. Auer,et al.  Polypeptide Expression in Prostate Hyperplasia and Prostate Adenocarcinoma , 2000, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.